Electrocardiographic changes in early recognition of Fabry disease

Heart

Volumn 97, Issue 6, 2011, Pages 485-490

  Namdar, Mehdi ^a,b   Steffel, Jan ^a   Vidovic, Mile ^a   Brunckhorst, Corinna B ^a   Holzmeister, Johannes ^a   Lüscher, Thomas F ^a,c   Jenni, Rolf ^a,c   Duru, Firat ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ECG ABNORMALITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FABRY DISEASE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HEART REPOLARIZATION; HUMAN; MALE; P WAVE; PQ INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT DISPERSION; SENSITIVITY AND SPECIFICITY;

ADULT; ARRHYTHMIAS, CARDIAC; EARLY DIAGNOSIS; ELECTROCARDIOGRAPHY; EPIDEMIOLOGIC METHODS; FABRY DISEASE; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79952004058     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.211789     Document Type: Article

References (39)

1. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-46. (Pubitemid 36205932)
2. Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008;93:112-28.
3. Cybulla M, Walter K, Neumann HP, et al. [Fabry disease: demographic data since introduction of enzyme replacement therapy] (In German). Dtsch Med Wochenschr 2007;132:1505-9.
4. Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry Outcome Survey. Eur Heart J 2007;28:1228-35. (Pubitemid 47343855)
5. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009;119:524-9.
6. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539-48. (Pubitemid 44402030)
7. Barbey F, Qanadli SD, Juli C, et al. Aortic remodelling in Fabry disease. Eur Heart J 2009;31:347-53.
8. Brakch N, Dormond O, Bekri S, et al. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J 2010;31:67-76.
9. Takenaka T, Teraguchi H, Yoshida A, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 2008;51:50-9. (Pubitemid 351699928)
10. Namdar M, Kampmann C, Steffel J, et al. PQ interval in patients with Fabry disease. Am J Cardiol 2010;105:753-6.
11. Mehta J, Tuna N, Moller JH, et al. Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease. Am Heart J 1977;93:699-705. (Pubitemid 8201083)
12. Pochis WT, Litzow JT, King BG, et al. Electrophysiologic findings in Fabry's disease with a short PR interval. Am J Cardiol 1994;74:203-4. (Pubitemid 24219320)
13. Perkiomaki JS, Koistinen MJ, Yli-Mayry S, et al. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol 1995;26:174-9.
14. Chiladakis J, Kalogeropoulos A, Arvanitis P, et al. Heart rate-dependence of QTc intervals assessed by different correction methods in patients with normal or prolonged repolarization. Pacing Clin Electrophysiol 2009;33:553-60.
15. Antzelevitch C, Shimizu W, Yan GX, et al. Cellular basis for QT dispersion. J Electrocardiol 1998;30(Suppl):168-75. (Pubitemid 28145056)
16. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998;98:1928-36. (Pubitemid 28509291)
17. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8. (Pubitemid 16119719)
18. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-18.
19. Jenni R, Vieli A, Hess O, et al. Estimation of left ventricular volume from apical orthogonal 2-D echocardiograms. Eur Heart J 1981;2:217-25. (Pubitemid 11092753)
20. Khouri SJ, Maly GT, Suh DD, et al. A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr 2004;17:290-7. (Pubitemid 38879266)
21. Josephson ME. Clinical cardiac electrophysiology: Techniques and interpretations. 4th edn. Philadelphia: Wolters Kluwer, Lippincott Williams and Wilkins, 2008.
22. Stemper B, Hilz MJ. Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease. J Neurol 2003;250:970-6. (Pubitemid 37041030)
23. Hilz MJ, Stemper B, Kolodny EH. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain 2000;84:361-5. (Pubitemid 30074239)
24. Jastrzebski M, Bacior B, Dimitrow PP, et al. Electrophysiological study in a patient with Fabry disease and a short PQ interval. Europace 2006;8:1045-7. (Pubitemid 44896798)
25. Aryana A, Fifer MA, Ruskin JN, et al. Short PR interval in the absence of preexcitation: a characteristic finding in a patient with Fabry disease. Pacing Clin Electrophysiol 2008;31:782-3. (Pubitemid 351749326)
26. Ramon F, Moore JW. Propagation of action potentials in squid giant axons. Repetitive firing at regions of membrane inhomogeneities. J Gen Physiol 1979;73:595-603.
27. Wolf CM, Arad M, Ahmad F, et al. Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Circulation 2008;117:144-54.
28. Waldek S. PR interval and the response to enzyme-replacement therapy for Fabry's disease. N Engl J Med 2003;348:1186-7. (Pubitemid 36337339)
29. Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 2004;66:158-65. (Pubitemid 39117524)
30. Peters RW, Byington RP, Barker A, et al. Prognostic value of prolonged ventricular repolarization following myocardial infarction: the BHAT experience. The BHAT Study Group. J Clin Epidemiol 1990;43:167-72. (Pubitemid 20062809)
31. Moss AJ, Robinson J. Clinical features of the idiopathic long QT syndrome. Circulation 1992;85:I140-4.
32. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47:362-7. (Pubitemid 43063255)
33. Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005;96:842-6. (Pubitemid 41319722)
34. Faber TS, Kautzner J, Zehender M, et al. Impact of electrocardiogram recording format on QT interval measurement and QT dispersion assessment. Pacing Clin Electrophysiol 2001;24:1739-47. (Pubitemid 34066778)
35. Kautzner J, Malik M. QT interval dispersion and its clinical utility. Pacing Clin Electrophysiol 1997;20:2625-40.
36. Kautzner J, Yi G, Camm AJ, et al. Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. Pacing Clin Electrophysiol 1994;17:928-37.
37. Weidemann F, Strotmann J. Early detection of Fabry disease: cardiac cases. Clin Ther 2008;30(Suppl B):S46. (Pubitemid 351458358)
38. Toro R, Perez-Isla L, Doxastaquis G, et al. Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 2009;132:38-44.
39. Hoigne P, Attenhofer Jost CH, Duru F, et al. Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy. Int J Cardiol 2006;111:413-22. (Pubitemid 44205296)